The DRG1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the DRG1 gene has been disrupted. This polyclonal model provides a genetically diverse pool of cells, maintaining population-level representation and avoiding clonal selection artifacts. The CRISPR/Cas9-mediated gene disruption generates a loss-of-function model suitable for studying DRG1-dependent processes without the need for single-cell clone isolation. These cells offer a robust system to investigate gene function in a cervical cancer context.
The host HeLa cell line is an immortalized human cervical epithelial carcinoma line positive for HPV18. Widely used in biomedical research, HeLa cells exhibit robust proliferation and have a well-characterized genome. Their origin from cervical adenocarcinoma and ease of genetic manipulation make them an ideal platform for creating knockout models to study oncogenic signaling and cell cycle regulation.
DRG1 encodes a highly conserved GTPase essential for ribosome biogenesis and translational control. It functions downstream of mTORC1, responding to nutrient availability and growth factor signals. DRG1 interacts with partners including DRG2, ZC3H15, TMA46, and ribosomal proteins RPS3 and RPL4 to regulate translation initiation factors eIF4E and eEF2. This interaction network positions DRG1 as a key link between growth signaling and the protein synthesis machinery.
In HeLa cells, DRG1 disruption impairs ribosome biogenesis and protein synthesis, potentially reducing proliferation and oncogenic traits. The active mTOR pathway in HeLa cells provides a relevant background to examine how DRG1 integrates mitogenic signals into translational output. Loss of DRG1 function may alter ribosomal protein expression and translation dynamics, offering a model to dissect translational control in cervical adenocarcinoma.
These polyclonal knockout cells are applicable to cancer cell biology, translational regulation studies, functional genomics screening, and drug target validation. Assays such as cell proliferation, clonogenic survival, Western blotting for RPS6, polysome profiling, and puromycin incorporation can assess growth and translation phenotypes. This model enables exploration of DRG1??s role in protein synthesis and its potential as a therapeutic vulnerability. For more information, contact Ascent Research.
